drugset / Trial / NCT03454048
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
Completed
24 enrolled
Radboud University Medical Center
QIMR Berghofer Medical Research Institute · collabThe PATH Malaria Vaccine Initiative (MVI) · collab
RandomizedParallel-groupOpen-labelOther
Summary
This is a single-center, open label study. The primary aim of this project is to develop a controlled human malaria infection transmission model ("CHMI-trans") or "challenge model" to evaluate the capacity of vaccines, biologics (monoclonal antibodies, or mAbs), and drugs to block malaria parasite transmission by assessing infectiousness of Plasmodium falciparum (Pf) gametocyte carriers for Anopheles mosquitoes.
Timeline
- Start
- 2018-05-07
- Primary completion
- 2018-11-01
- Completion
- 2018-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | piperaquine | Small molecule | 480 mg | Oral |
| Subject | piperaquine | Small molecule | 960 mg | Oral |
| Subject | pyrimethamine | Small molecule | 50 mg | — |
| Subject | sulfadoxine | Small molecule | 1000 mg | — |
| Background | Atovaquone | Small molecule | 1000 mg | — |
| Background | Proguanil | Small molecule | 400 mg | — |